Strategy

Johnson & Johnson announced a massive restructuring plan on Tuesday in an effort to save $1.4 billion to $1.7 billion by 2011. The human cost: 7 percent of its workforce.

A novel joint venture between Glaxo and Pfizer is big on promise. But the combined portfolio and pipeline of HIV drugs? Not so much.

Sure, industry growth is at "historically low levels," but at least pharma is still growing. The industry's market value should surpass $825 billion in 2010, and forecasted growth was bumped up one percentage point from original estimates.

Pulling off an incredibly fast turnaround, the pharma industry has released a vaccine for the H1N1 virus, bolstering its bottom line with a second flu vaccine and potentially helping millions of people. So why is there such an uproar over whether it's safe?

Novartis CEO Daniel Vasella has built the Swiss firm into the fastest growing pharma in the world, and in the process gained a reputation as an outspoken visionary. But is he really as good as all that?

Just months on the job and GSK’s new president of North American Pharmaceuticals Deirdre Connelly is already making her presence known. Her latest move-spearheading an initiative that will boost funding to autonomous CME programs and cut commercial medical education programs. Pharm Exec spoke with Connelly to find out more.

Eli Lilly announced this morning that it would eliminate approximately 5,500 positions as part of a massive reorganization strategy that's expected to net the firm reduce $1 billion in costs by 2011.

The obesity pipeline, despite a hugely underserved market potentially worth $11 billion, is awfully thin.

The President and Congress are sounding the alarm on the need for healthcare reform. There are several near-certainties for which pharmaceutical and biotechnology companies must be prepared as they develop forecasts and for the next five or six years.

With the biotech industry reeling from the recession, big drugmakers hold all the cards when it comes to making deals, but picking a winner is still a gamble. Here are 10 to place stakes on.

The sponsors of clinical trials Sunshine Act legislation to improve their physician payment processes, educate the public on the complexity of clinical research and development, and help patients make informed opinions about physicians - bringing true transparency to the financial aspects of discovering new medical treatments.

Sanofi-Aventis is banking that its highly anticipated atrial fibrillation/flutter treatment Multaq will be a huge success. The path to approval has been ridden with a failed trial and a very long review process, but for Sanofi, the wait has been worth it.

Oscient trims 180 sales, marketing, and corporate jobs in the wake of patent expirations, generic competition.

Our second annual Emerging Leadership Awards cast the spotlight on 27 young rising stars most notable for their dedication and contribution to the pharma industry. Here's a closer look at why.

The P4P movement is here. Pharma marketers, it's time to take note.

As it readies submission for a once-weekly diabetes injectable, Amylin announces that it will trim 35 percent of its sales force and put focus on specialty physicians.

Pharm Exec Europe's Gerhard Symons speaks to Andrew Jones, a senior pharmaceutical analyst with the firm, about the value of introducing a "risk radar" to your organization.

When it comes to licensing in this market, there are winners and losers. Learn the new rules of the game.

As the US government weighs its options on whether to commission a vaccine for the new H1N1 strain of influenza, pharma companies gear up for a possible epidemic.

In an effort to realign its sales division to reflect the current pharma environment-smaller, faster, better-Johnson & Johnson is trimming its sales force.

A company’s trade secrets and the goodwill it has developed can mean the difference between a blockbuster and a failure. Here’s what you should know and do to properly negotiate post-employment agreements.

Just two months after the purchase of Wyeth, Pfizer breaks its research division into two-one for large molecules and vaccines, and another for small molecules-with Wyeth and Pfizer execs at the helms.

From her start as a physician working in apartheid-era South Africa to the dramatic turnaround and takeover of Millennium, Deborah Dunsire has lived a life that has defied all expectations.

"Best Pharma not Big Pharma" is Merck Serono head Elmar Schnee's business philosophy. He tells Pharm Exec Europe how the Swiss-based company aims to achieve that goal, and points out the current political obstacles.

Now that Vyvanse, Shire's innovative ADD drug, has been approved for adults, the company needs help to quickly roll out a complex message to neurologists. Its solution: a partnership that takes advantage of GSK's CNS muscle.